2977 related articles for article (PubMed ID: 31005597)
1. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
2. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
3. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
4. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
6. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
[TBL] [Abstract][Full Text] [Related]
7. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
9. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
11. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
12. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
13. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
14. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
[TBL] [Abstract][Full Text] [Related]
15. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
16. CARs and other T cell therapies for MM: The clinical experience.
Danhof S; Hudecek M; Smith EL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):147-157. PubMed ID: 29909915
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
Front Immunol; 2019; 10():1613. PubMed ID: 31379824
[TBL] [Abstract][Full Text] [Related]
18. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
[TBL] [Abstract][Full Text] [Related]
19. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
20. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
O'Neal J; Cooper ML; Ritchey JK; Gladney S; Niswonger J; González LS; Street E; Haas GJ; Carter A; Amayta PN; Gao F; Lee BH; Choi D; Berrien-Elliott M; Zhou A; Fehniger TA; Rettig MP; DiPersio JF
Blood Adv; 2023 Oct; 7(20):6009-6022. PubMed ID: 37399471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
